{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-110612","form_type":"8-K","ticker":"ABT","cik":"0000001800","company_name":"ABBOTT LABORATORIES","filed_at":"2022-10-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.171793+00:00","generated_at":"2026-06-23T02:00:26.058053+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Abbott extends change-in-control agreements with named executive officers through Dec 2024","bullets":["Extension moves expiration date from Dec 31, 2022 to Dec 31, 2024 for named executive officers.","Agreements provide severance and other benefits upon a change in control of the company.","Previously reported Agreements with executive officers extended by two years effective Oct 18, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-110612","json":"https://secwatch.observer/filing/0001104659-22-110612.json","markdown":"https://secwatch.observer/filing/0001104659-22-110612.md","text":"https://secwatch.observer/filing/0001104659-22-110612.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800/000110465922110612/0001104659-22-110612-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800/000110465922110612/tm2228558d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T02:00:26.058053+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}